Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
> 26 27 26 27 O
250/ 28 32 28 32 B-lower_bound
µL 33 35 33 35 I-lower_bound
( 36 37 36 37 O
may 37 40 37 40 O
be 41 43 41 43 O
supported 44 53 44 53 O
with 54 58 54 58 O
GCSF 59 63 59 63 B-clinical_variable
) 63 64 63 64 O

Active 0 6 65 71 O
Bronchiolitis 7 20 72 85 B-chronic_disease
obliterans 21 31 86 96 I-chronic_disease
syndrome 32 40 97 105 I-chronic_disease

Acute 0 5 106 111 B-cancer
lymphoblastic 6 19 112 125 I-cancer
leukemia 20 28 126 134 I-cancer
( 29 30 135 136 I-cancer
ALL 30 33 136 139 I-cancer
) 33 34 139 140 I-cancer

Acute 0 5 141 146 B-cancer
myeloid 6 13 147 154 I-cancer
leukemia 14 22 155 163 I-cancer
( 23 24 164 165 I-cancer
AML 24 27 165 168 I-cancer
) 27 28 168 169 I-cancer

Aged 0 4 170 174 B-age
6 5 6 175 176 B-lower_bound
months 7 13 177 183 I-lower_bound
to 14 16 184 186 O
80 17 19 187 189 B-upper_bound
years 20 25 190 195 I-upper_bound

Agree 0 5 196 201 B-contraception_consent
to 6 8 202 204 I-contraception_consent
use 9 12 205 208 I-contraception_consent
contraceptive 13 26 209 222 I-contraception_consent
measures 27 35 223 231 O
during 36 42 232 238 O
study 43 48 239 244 O
protocol 49 57 245 253 O
participation 58 71 254 267 O
( 72 73 268 269 O
when 73 77 269 273 O
age 78 81 274 277 B-age
appropriate 82 93 278 289 O
) 93 94 289 290 O

Ambiguous 0 9 291 300 O
lineage 10 17 301 308 O
leukemia 18 26 309 317 B-cancer
or 27 29 318 320 O
lymphoma 30 38 321 329 B-cancer

Bilirubin 0 9 330 339 B-clinical_variable
< 10 11 340 341 O
2.5 12 15 342 345 B-upper_bound
mg 16 18 346 348 I-upper_bound
/ 18 19 348 349 I-upper_bound
dL 19 21 349 351 I-upper_bound
, 21 22 351 352 O
AST 23 26 353 356 B-clinical_variable
/ 26 27 356 357 O
ALT 27 30 357 360 B-clinical_variable
< 31 32 361 362 O
5x 32 34 362 364 B-upper_bound
upper 35 40 365 370 I-upper_bound
limit 41 46 371 376 I-upper_bound
of 47 49 377 379 I-upper_bound
normal 50 56 380 386 I-upper_bound
, 56 57 386 387 O
Serum 58 63 388 393 B-clinical_variable
creatinine 64 74 394 404 I-clinical_variable
< 75 76 405 406 O
1.0 77 80 407 410 B-upper_bound
or 81 83 411 413 I-upper_bound
2x 84 86 414 416 I-upper_bound
the 87 90 417 420 I-upper_bound
upper 91 96 421 426 I-upper_bound
limit 97 102 427 432 I-upper_bound
of 103 105 433 435 I-upper_bound
normal 106 112 436 442 I-upper_bound
( 113 114 443 444 O
whichever 114 123 444 453 O
is 124 126 454 456 O
higher 127 133 457 463 O
) 133 134 463 464 O

Chronic 0 7 465 472 B-cancer
Myelogenous 8 19 473 484 I-cancer
leukemia 20 28 485 493 I-cancer
, 28 29 493 494 O
MDS 30 33 495 498 B-cancer

Current 0 7 499 506 O
evidence 8 16 507 515 O
of 17 19 516 518 O
GVHD 20 24 519 523 O
> 25 26 524 525 O
grade 27 32 526 531 B-lower_bound
2 33 34 532 533 I-lower_bound
for 35 38 534 537 O
Arm 39 42 538 541 O
A 43 44 542 543 O
and 45 48 544 547 O
B 49 50 548 549 O
; 50 51 549 550 O
Active 52 58 551 557 O
GVHD 59 63 558 562 O
of 64 66 563 565 O
any 67 70 566 569 O
grade 71 76 570 575 O
is 77 79 576 578 O
exclusion 80 89 579 588 O
for 90 93 589 592 O
arm 94 97 593 596 O
C 98 99 597 598 O
patients 100 108 599 607 O

Current 0 7 608 615 O
evidence 8 16 616 624 O
of 17 19 625 627 O
GVHD 20 24 628 632 B-clinical_variable
> 25 26 633 634 O
grade 27 32 635 640 B-lower_bound
2 33 34 641 642 I-lower_bound
or 35 37 643 645 O
bronchiolitis 38 51 646 659 B-chronic_disease
obliterans 52 62 660 670 I-chronic_disease
syndrome 63 71 671 679 I-chronic_disease
, 71 72 679 680 O
sclerotic 73 82 681 690 B-chronic_disease
GVHD 83 87 691 695 I-chronic_disease
, 87 88 695 696 O
or 89 91 697 699 O
serositis 92 101 700 709 B-pregnancy
Pregnancy 102 111 710 719 I-pregnancy
or 112 114 720 722 O
lactating 115 124 723 732 O
( 125 126 733 734 O
female 126 132 734 740 B-gender
of 133 135 741 743 O
childbearing 136 148 744 756 O
potential 149 158 757 766 O
) 158 159 766 767 O

Evidence 0 8 768 776 O
of 9 11 777 779 O
HD 12 14 780 782 B-chronic_disease
by 15 17 783 785 O
morphology 18 28 786 796 O
, 28 29 796 797 O
PET 30 33 798 801 B-treatment
/ 33 34 801 802 I-treatment
CT 34 36 802 804 I-treatment
uptake 37 43 805 811 O
in 44 46 812 814 O
a 47 48 815 816 O
site 49 53 817 821 O
of 54 56 822 824 O
previous 57 65 825 833 O
disease 66 73 834 841 O
in 74 76 842 844 O
the 77 80 845 848 O
absence 81 88 849 856 O
of 89 91 857 859 O
other 92 97 860 865 O
etiologies 98 108 866 876 O
ARM 109 112 877 880 O
C 113 114 881 882 O
only 115 119 883 887 O
includes 120 128 888 896 O
patients 129 137 897 905 O
with 138 142 906 910 O
high 143 147 911 915 O
risk 148 152 916 920 O
AML 153 156 921 924 B-cancer
and 157 160 925 928 O
MDS 161 164 929 932 B-cancer
who 165 168 933 936 O
have 169 173 937 941 O
received 174 182 942 950 O
an 183 185 951 953 O
alloBMT 186 193 954 961 B-treatment
and 194 197 962 965 O
have 198 202 966 970 O
not 203 206 971 974 O
had 207 210 975 978 O
hematologic 211 222 979 990 O
relapse 223 230 991 998 O
of 231 233 999 1001 O
disease 234 241 1002 1009 O

Evidence 0 8 1010 1018 O
of 9 11 1019 1021 O
active 12 18 1022 1028 O
leukemia 19 27 1029 1037 B-cancer
or 28 30 1038 1040 O
lymphoma 31 39 1041 1049 B-cancer
disease 40 47 1050 1057 I-cancer
by 48 50 1058 1060 O
flow 51 55 1061 1065 B-treatment
cytometry 56 65 1066 1075 I-treatment
, 65 66 1075 1076 O
morphology 67 77 1077 1087 O
, 77 78 1087 1088 O
or 79 81 1089 1091 O
cytogenetic 82 93 1092 1103 O
evaluation 94 104 1104 1114 O
within 105 111 1115 1121 O
the 112 115 1122 1125 O
marrow 116 122 1126 1132 O
or 123 125 1133 1135 O
extramedullary 126 140 1136 1150 O
sites 141 146 1151 1156 O

For 0 3 1157 1160 O
allogeneic 4 14 1161 1171 B-treatment
HSCT 15 19 1172 1176 I-treatment
recipients 20 30 1177 1187 O
PD-1 31 35 1188 1192 B-treatment
inhibitors 36 46 1193 1203 I-treatment
or 47 49 1204 1206 O
other 50 55 1207 1212 O
T 56 57 1213 1214 B-treatment
cell 58 62 1215 1219 I-treatment
activating 63 73 1220 1230 I-treatment
agents 74 80 1231 1237 I-treatment

Hodgkin 0 7 1238 1245 B-cancer
's 7 9 1245 1247 I-cancer
Lymphoma 10 18 1248 1256 I-cancer
that 19 23 1257 1261 O
has 24 27 1262 1265 O
failed 28 34 1266 1272 O
or 35 37 1273 1275 O
are 38 41 1276 1279 O
intolerant 42 52 1280 1290 O
of 53 55 1291 1293 O
Brentuximab 56 67 1294 1305 B-treatment
, 67 68 1305 1306 O
Grey 69 73 1307 1311 B-cancer
Zone 74 78 1312 1316 I-cancer
Lymphoma 79 87 1317 1325 I-cancer
, 87 88 1325 1326 O
ALCL 89 93 1327 1331 B-cancer
, 93 94 1331 1332 O
and 95 98 1333 1336 O
mantle 99 105 1337 1343 B-cancer
cell 106 110 1344 1348 I-cancer
lymphoma 111 119 1349 1357 I-cancer

If 0 2 1358 1360 O
the 3 6 1361 1364 O
product 7 14 1365 1372 O
is 15 17 1373 1375 O
procured 18 26 1376 1384 O
from 27 31 1385 1389 O
the 32 35 1390 1393 O
recipient 36 45 1394 1403 O
either 46 52 1404 1410 O
in 53 55 1411 1413 O
the 56 59 1414 1417 O
autologous 60 70 1418 1428 O
( 71 72 1429 1430 O
Arm 72 75 1430 1433 O
B 76 77 1434 1435 O
) 77 78 1435 1436 O
or 79 81 1437 1439 O
allogeneic 82 92 1440 1450 O
( 93 94 1451 1452 O
Arm 94 97 1452 1455 O
A 98 99 1456 1457 O
) 99 100 1457 1458 O
setting 101 108 1459 1466 O
, 108 109 1466 1467 O
the 110 113 1468 1471 O
absolute 114 122 1472 1480 O
lymphocyte 123 133 1481 1491 B-clinical_variable
count 134 139 1492 1497 I-clinical_variable
should 140 146 1498 1504 O
be 147 149 1505 1507 O
greater 150 157 1508 1515 O
than 158 162 1516 1520 O
or 163 165 1521 1523 O
equal 166 171 1524 1529 O
to 172 174 1530 1532 O
600 175 178 1533 1536 B-lower_bound
for 179 182 1537 1540 O
procurement 183 194 1541 1552 O

Karnofsky 0 9 1553 1562 B-clinical_variable
/ 9 10 1562 1563 O
Lansky 10 16 1563 1569 B-clinical_variable
score 17 22 1570 1575 I-clinical_variable
of 23 25 1576 1578 O
≥ 26 27 1579 1580 O
50 28 30 1581 1583 B-lower_bound

No 0 2 1584 1586 O
investigational 3 18 1587 1602 B-treatment
therapies 19 28 1603 1612 I-treatment
( 29 30 1613 1614 O
under 30 35 1614 1619 O
IND 36 39 1620 1623 O
, 39 40 1623 1624 O
not 41 44 1625 1628 O
extensively 45 56 1629 1640 O
studied 57 64 1641 1648 O
in 65 67 1649 1651 O
the 68 71 1652 1655 O
current 72 79 1656 1663 O
clinical 80 88 1664 1672 O
context 89 96 1673 1680 O
) 96 97 1680 1681 O
within 98 104 1682 1688 O
the 105 108 1689 1692 O
last 109 113 1693 1697 B-upper_bound
28 114 116 1698 1700 I-upper_bound
days 117 121 1701 1705 I-upper_bound

Patients 0 8 1706 1714 O
( 9 10 1715 1716 O
Arm 10 13 1716 1719 O
A 14 15 1720 1721 O
) 15 16 1721 1722 O
who 17 20 1723 1726 O
have 21 25 1727 1731 O
undergone 26 35 1732 1741 O
allo 36 40 1742 1746 B-treatment
- 40 41 1746 1747 I-treatment
HSCT 41 45 1747 1751 I-treatment
with 46 50 1752 1756 O
high 51 55 1757 1761 O
risk 56 60 1762 1766 O
for 61 64 1767 1770 O
relapse 65 72 1771 1778 O
or 73 75 1779 1781 O
residual 76 84 1782 1790 O
/ 84 85 1790 1791 O
recurrent 85 94 1791 1800 O
disease 95 102 1801 1808 O

Patients 0 8 1809 1817 O
who 9 12 1818 1821 O
received 13 21 1822 1830 O
ATG 22 25 1831 1834 B-treatment
, 25 26 1834 1835 O
Campath 27 34 1836 1843 B-treatment
, 34 35 1843 1844 O
or 36 38 1845 1847 O
other 39 44 1848 1853 O
T 45 46 1854 1855 B-treatment
cell 47 51 1856 1860 I-treatment
immunosuppressive 52 69 1861 1878 I-treatment
monoclonal 70 80 1879 1889 I-treatment
antibodies 81 91 1890 1900 I-treatment
in 92 94 1901 1903 O
the 95 98 1904 1907 O
last 99 103 1908 1912 B-upper_bound
28 104 106 1913 1915 I-upper_bound
days 107 111 1916 1920 I-upper_bound

Patients 0 8 1921 1929 O
with 9 13 1930 1934 O
HIV 14 17 1935 1938 B-chronic_disease
infection 18 27 1939 1948 O

Patients 0 8 1949 1957 O
with 9 13 1958 1962 O
uncontrolled 14 26 1963 1975 B-chronic_disease
infections 27 37 1976 1986 I-chronic_disease

Pregnancy 0 9 1987 1996 B-pregnancy

Pulse 0 5 1997 2002 B-clinical_variable
oximetry 6 14 2003 2011 I-clinical_variable
of 15 17 2012 2014 O
> 18 19 2015 2016 O
90 20 22 2017 2019 B-lower_bound
% 22 23 2019 2020 I-lower_bound
on 24 26 2021 2023 O
room 27 31 2024 2028 O
air 32 35 2029 2032 O

Received 0 8 2033 2041 O
prior 9 14 2042 2047 B-treatment
or 15 17 2048 2050 I-treatment
anticipated 18 29 2051 2062 I-treatment
myeloablative 30 43 2063 2076 I-treatment
or 44 46 2077 2079 I-treatment
non 47 50 2080 2083 I-treatment
- 50 51 2083 2084 I-treatment
myeloablative 51 64 2084 2097 I-treatment
allogeneic 65 75 2098 2108 I-treatment
hematopoietic 76 89 2109 2122 I-treatment
stem 90 94 2123 2127 I-treatment
cell 95 99 2128 2132 I-treatment
transplant 100 110 2133 2143 I-treatment

Steroids 0 8 2144 2152 B-treatment
less 9 13 2153 2157 O
than 14 18 2158 2162 O
0.5 19 22 2163 2166 B-upper_bound
mg 23 25 2167 2169 I-upper_bound
/ 25 26 2169 2170 I-upper_bound
kg 26 28 2170 2172 I-upper_bound
/ 28 29 2172 2173 I-upper_bound
day 29 32 2173 2176 I-upper_bound
prednisone 33 43 2177 2187 B-treatment
( 44 45 2188 2189 O
or 45 47 2189 2191 O
equivalent 48 58 2192 2202 O
) 58 59 2202 2203 O

Total 0 5 2204 2209 B-clinical_variable
chimerism 6 15 2210 2219 I-clinical_variable
> 16 17 2220 2221 O
50 18 20 2222 2224 B-lower_bound
% 20 21 2224 2225 I-lower_bound

Uncontrolled 0 12 2226 2238 B-chronic_disease
infections 13 23 2239 2249 I-chronic_disease

lactating 0 9 2250 2259 O
( 10 11 2260 2261 O
female 11 17 2261 2267 B-gender
of 18 20 2268 2270 O
childbearing 21 33 2271 2283 O
potential 34 43 2284 2293 O
) 43 44 2293 2294 O

patients 0 8 2295 2303 O
( 9 10 2304 2305 O
Arm 10 13 2305 2308 O
B 14 15 2309 2310 O
) 15 16 2310 2311 O
with 17 21 2312 2316 O
relapsed 22 30 2317 2325 B-chronic_disease
/ 30 31 2325 2326 I-chronic_disease
refractory 31 41 2326 2336 I-chronic_disease
disease 42 49 2337 2344 I-chronic_disease
( 50 51 2345 2346 O
> 51 52 2346 2347 O
2 53 54 2348 2349 B-lower_bound
regimens 55 63 2350 2358 O
with 64 68 2359 2363 O
greater 69 76 2364 2371 O
than 77 81 2372 2376 O
M1 82 84 2377 2379 B-clinical_variable
marrow 85 91 2380 2386 I-clinical_variable
or 92 94 2387 2389 O
persistent 95 105 2390 2400 B-clinical_variable
HD 106 108 2401 2403 I-clinical_variable
) 108 109 2403 2404 O
with 110 114 2405 2409 O
anticipated 115 126 2410 2421 O
allo 127 131 2422 2426 B-treatment
- 131 132 2426 2427 I-treatment
HSCT 132 136 2427 2431 I-treatment
pre- 137 141 2432 2436 B-treatment
and/or 142 148 2437 2443 I-treatment
post 149 153 2444 2448 I-treatment
- 153 154 2448 2449 I-treatment
HSCT 154 158 2449 2453 I-treatment

sclerotic 0 9 2454 2463 O
GVHD 10 14 2464 2468 B-chronic_disease

serositis 0 9 2469 2478 B-chronic_disease

